GeoVax Highlights MVA Vaccine Platform for Ebola and Marburg Threats

As the Bundibugyo Ebola virus outbreak escalates in Central Africa, declared a Public Health Emergency of International Concern by the WHO, Atlanta-based GeoVax Labs, Inc. (Nasdaq: GOVX) is highlighting the potential of its MVA-based vaccine platform to address emerging hemorrhagic fever threats, including Ebola and Marburg viruses. GeoVax’s preclinical data show single-dose protection against Zaire Ebola, Sudan Ebola, and Marburg viruses in non-human primates, underscoring the platform’s adaptability to multiple filovirus targets. The current outbreak, involving a species without a licensed vaccine, exposes gaps in strain-specific preparedness and reinforces the need for flexible technologies like GeoVax’s MVA platform, which offers established safety, multivalent potential, and rapid adaptation capabilities.

GeoVax CEO David A. Dodd emphasized that “preparedness against one viral strain does not necessarily ensure preparedness against the next,” pointing to the growing era of continuous disease emergence. The company is also advancing GEO-MVA, an MVA-based vaccine targeting mpox and smallpox, with a pivotal Phase 3 study slated for Q4 2026. This program aims to bolster domestic U.S. MVA manufacturing capacity and support global orthopox preparedness. The broader strategic relevance of MVA technologies is expanding as governments prioritize supply-chain resilience, domestic manufacturing, and flexible platforms to counter multiple high-consequence pathogens. GeoVax believes its platform can enable multivalent single-dose vaccines targeting several hemorrhagic fever viruses simultaneously, a critical advantage for biodefense.

With the WHO’s PHEIC declaration highlighting global readiness challenges, GeoVax’s MVA-based vaccine technologies offer a promising solution for rapid response. The company’s preclinical successes across Ebola and Marburg strains suggest that its platform could fill critical gaps in current biodefense infrastructure. As the outbreak evolves, the need for diversified manufacturing and scalable vaccine platforms becomes increasingly urgent, positioning GeoVax at the forefront of next-generation pandemic preparedness. For more details, view the original release on NEWMEDIAWIRE.